Aldesleukin by Iovance Biotherapeutics for Graft Versus Host Disease (GVHD): Likelihood of Approval

Aldesleukin is under clinical development by Iovance Biotherapeutics and currently in Phase II for Graft Versus Host Disease (GVHD).

Early-Stage GLP-1 Win in Obesity; An Argument for BMI’s Value; Insulin Supply Issues

Participants in a phase I trial lost a placebo-adjusted 6.1% of their body weight after 4 weeks of treatment with the investigational oral GLP-1 receptor

July 24, 2024

Smartwatch bands may expose users to harmful forever chemicals

Smartwatches and fitness trackers have become ubiquitous forms of wearable tech, accompanying many people throughout their days (and nights).

December 19, 2024

Study reveals significant deficit in the UK’s prosthetic and orthotic workforce

A Staffordshire University study has revealed a significant deficit in the number of prosthetists, orthotists, prosthetic and orthotic technicians, and support workers in the UK.

November 6, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.